Washington D.C., Jan. 27, 2025– Global Alzheimer’s Platform Foundation® (GAP) applauds the U.S. Food and Drug Administration (FDA)’s approval of IV maintenance dosing for the treatment LEQEMBI®. With this approval, after a patient completes 18 months of once every two weeks initiation phase, a transition to the maintenance dosing regimen of once every four weeks may be considered.
John Dwyer, President of the Global Alzheimer’s Platform Foundation stated, “We congratulate Eisai and Biogen on the FDA approval for the IV maintenance dosing of LEQEMBI. The convenience of providing the therapy once every four weeks will make it easier for eligible patients to receive this disease-modifying medication on a reasonable schedule, increasing the chances that they can continue with the treatment. It is a step in the right direction that will improve the lives of people living with Alzheimer’s disease.”
For immediate release:
Contact: media@globalalzplatform.org
About the Global Alzheimer’s Platform Foundation (GAP):
The nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and duration of clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible.